GA-DYSIS-MEDICAL-INC.
DYSIS Medical Inc. is excited to announce the launch of DYSIS® View, a compact and portable colposcope, which includes the company’s innovative computer-aided cervical mapping technology that helps healthcare professionals detect cervical lesions more clearly.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005846/en/
The DYSIS family of colposcopes include the novel DYSISmap, which is a color-coded summary of the acetowhitening effect of the patient’s cervix. Colors are allocated on the map depending on the acetowhitening changes measured by DYSIS during the examination. This data helps healthcare professionals improve biopsy selection. In the IMPROVE-COLPO study, when map-assisted biopsies were added to colposcopy exams, detection of patients with CIN2+ increased by 44%1 .
“We are thrilled to bring DYSIS View to market to complement our already strong presence with DYSIS Ultra,” said Darin Hammers, CEO of DYSIS Medical. “While DYSIS View is much more compact and portable than our previous colposcope designs, it’s equal in sophistication and technology. It fills a gap in the market where we’re able to provide our innovative mapping technology to a wide range of healthcare professionals.”
In addition to the innovative cervical mapping technology, DYSIS View includes a camera for high resolution exam videos and images, instant replay of colposcopy exams, DYSIS SMARTtrack™ to compare a patient’s DYSIS View colposcopy exams and a patient database for record storage. Find out more about the new DYSIS View colposcope at dysismedical.com .
About DYSIS Medical
DYSIS Medical Inc. is based in Atlanta, Georgia. The Company is committed to early detection and diagnosis of cervical disease using biophotonic innovations. DYSIS is committed to becoming the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit dysismedical.com
.
1 DeNardis et al. Int J Womens Health. 2017; 9: 717–725.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005846/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)17.11.2025 07:00:00 CET | Press release
Pending the European Commission decision, Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide will represent an important new therapeutic option from second line for patients with follicular lymphoma (FL) in EuropeIn Western countries, relapsed or refractory FL affects 2-4 out of every 100,000 people1The positive Committee for Medicinal Products for Human Use (CHMP) recommendation is based on data from the Phase 3 inMIND trial which showed patients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide2 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at
ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline17.11.2025 07:00:00 CET | Press release
At ASDS 2025, Galderma unveiled pivotal new data from its range of pioneering Restylane® hyaluronic acid (HA) injectables, highlighting its versatility in improving the chin profile with Restylane Lyft™, temple volume with investigational Restylane Contour™* and skin quality in the décolletage (neckline) with investigational Restylane Skinboosters™*1-3 Nine-month results from a first-of-its-kind clinical trial were presented, reinforcing that the treatment regimen of Restylane Lyft or Restylane Contour with Sculptra® delivers sustained aesthetic facial improvements for patients experiencing facial aesthetic changes after medication-driven weight loss4 The company also presented new phase III data on its investigational product Relfydess™ (RelabotulinumtoxinA)* relating to its rapid onset as early as day one and long duration of effect on frown lines and crow’s feet5 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Inje
UBS and Ant International Partner on Blockchain-Based Real-Time Cross-Border Payments Settlement and Liquidity Management17.11.2025 05:42:00 CET | Press release
UBS has entered a strategic partnership with Ant International, a leading global digital payment, digitisation, and financial technology provider, to explore innovations in blockchain-based tokenised deposits to support Ant International’s global payments settlement and liquidity management. Both parties signed a Memorandum of Understanding (MoU) at UBS’s flagship office at 9 Penang Road in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116743090/en/ From left to right: Young Jin Yee, Co-Head UBS Global Wealth Management Asia Pacific and Country Head Singapore, Kay Tin Khoo, Head Corporate Institutional Clients Asia Pacific, UBS, Kelvin Li, General Manager of Platform Tech at Ant International, and Douglas Feagin, President of Ant International at the MoU signing ceremony at UBS Singapore office at 9 Penang Road. Under the MoU, Ant International will leverage UBS Digital Cash, a blockchain-based payment platfor
Nitto Extends Partnership with the ATP Until 203017.11.2025 04:24:00 CET | Press release
Nitto Denko Corporation (Headquarters: Osaka, Japan; President: Hideo Takasaki; hereafter “Nitto”)(TOKYO:6988) is pleased to announce the extension of its partnership with the ATP for an additional five years, through 2030. Under this renewed agreement, Nitto will continue its role as the Title Partner of the Nitto ATP Finals, the season-ending championship, in collaboration with the ATP and the Italian Tennis and Padel Federation (FITP). By sponsoring this tournament, recognized as one of the most sustainable events on the ATP Tour, Nitto aims to inspire and amaze while pursuing further growth as a global company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116197903/en/ Nitto Extends Partnership with the ATP Until 2030 : ©Corinne Dubreuil/ATP Tour Since 2017, Nitto has served as the Title Partner of the Nitto ATP Finals―the year-end climax of the men's professional tennis circuit featuring the world’s the top eight s
AIT Worldwide Logistics’ Global Expansion Continues With First Facility in Indonesia17.11.2025 04:01:00 CET | Press release
Jakarta office launches in response to demand for logistics expertise in Southeast Asia As part of its ongoing organic expansion strategy, global supply chain solutions leader, AIT Worldwide Logistics, opened its first office in Jakarta, Indonesia. The new facility represents the eighth country in the AIT-Asia network and exemplifies the company’s adaptability and flexibility in response to customer demands in the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116717860/en/ Teammates gathered to celebrate the grand opening of AIT-Jakarta. According to AIT’s Chief Strategy Officer, Greg Weigel, the team in Jakarta will collaborate with AIT’s expansive global network to quickly customize sea, air and road solutions unique to each client’s organizational needs, with a particular focus on the region’s flourishing industrial, technology and telecommunications sectors. “Jakarta is a pivotal market for us as we continue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom